BACKGROUND: the role of anxiety and depression in CD patients in remission has been poorly investigated. OBJECTIVE: the aim of the study was to evaluate the frequency of anxiety and depression symptoms in CD patients in remission, and potential factors influencing the development of these symptoms. METHODS: CD patients older than 18 years in remission for at least 6 months before study entry were included. CD remission was defined as a Crohn s Disease Activity Index (CDAI) < 150 points together with C-reactive protein < 5 mg/L. A demographic questionnaire was filled in, and all patients were clinically classified. The therapy maintaining remission was also recorded. A Hospital Anxiety and Depression scale (HAD) was administered to all patients. Results are shown as OR and 95% CI, and analyzed by logistic regression. RESULTS: 92 consecutive patients were included (48 male, mean age 37 years, range from 18 to 71 years). One patient failed to correctly fill in the questionnaire. Anxiety and depression symptoms were present in 36 (39%) and 22 (24%) patients, respectively. Infliximab therapy was the only factor associated with anxiety (OR = 3.11; 95% CI: 1.03-9.43; p < 0.05). In contrast, the presence of depressive symptoms is less frequent in patients under infliximab therapy (OR = 0.16; 95% CI: 0.02-0.97; p < 0.05). CONCLUSIONS: despite clinical remission, an important number of CD patients present with anxiety or depressive symptoms. Infliximab therapy in CD patients is associated to more anxiety but fewer depressive symptoms. CD patients in remission would probably benefit from psychological support.
BACKGROUND: the role of anxiety and depression in CDpatients in remission has been poorly investigated. OBJECTIVE: the aim of the study was to evaluate the frequency of anxiety and depression symptoms in CDpatients in remission, and potential factors influencing the development of these symptoms. METHODS:CDpatients older than 18 years in remission for at least 6 months before study entry were included. CD remission was defined as a Crohn s Disease Activity Index (CDAI) < 150 points together with C-reactive protein < 5 mg/L. A demographic questionnaire was filled in, and all patients were clinically classified. The therapy maintaining remission was also recorded. A Hospital Anxiety and Depression scale (HAD) was administered to all patients. Results are shown as OR and 95% CI, and analyzed by logistic regression. RESULTS: 92 consecutive patients were included (48 male, mean age 37 years, range from 18 to 71 years). One patient failed to correctly fill in the questionnaire. Anxiety and depression symptoms were present in 36 (39%) and 22 (24%) patients, respectively. Infliximab therapy was the only factor associated with anxiety (OR = 3.11; 95% CI: 1.03-9.43; p < 0.05). In contrast, the presence of depressive symptoms is less frequent in patients under infliximab therapy (OR = 0.16; 95% CI: 0.02-0.97; p < 0.05). CONCLUSIONS: despite clinical remission, an important number of CDpatients present with anxiety or depressive symptoms. Infliximab therapy in CDpatients is associated to more anxiety but fewer depressive symptoms. CDpatients in remission would probably benefit from psychological support.
Authors: Paris Tavakoli; Ute Vollmer-Conna; Dusan Hadzi-Pavlovic; Xabier Vázquez-Campos; Michael Carl Grimm Journal: Front Med (Lausanne) Date: 2022-07-19
Authors: Bobby Lo; Manuel Barreiro-de Acosta; Charles N Bernstein; Johan Burisch; Nuno Ferreira; Richard B Gearry; Antonina Mikocka-Walus; Anna Mokrowiecka; Inês A Trindade; Simon R Knowles Journal: Turk J Gastroenterol Date: 2022-08 Impact factor: 1.555